Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
2015 · Nature Medicine · 2,209 citations
https://doi.org/10.1038/nm.3850
M
Mark Ayers
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
106
Papers
15.8K
Citations
40
h-index
51
i10-index
Mark Ayers is an academic researcher from Merck & Co., Inc., Rahway, NJ, USA (United States). The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Colorectal Cancer Treatments and Studies & Cancer Genomics and Diagnostics. The author has an h-index of 40, co-authored 91 publications.
Papers by this author
worksBreast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
2005 · Clinical Cancer Research · 1,869 citations
https://doi.org/10.1158/1078-0432.ccr-04-2421
T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
2018 · Journal of Clinical Oncology · 965 citations
https://doi.org/10.1200/jco.2018.78.2276
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.
2003 · PubMed · 234 citations
HER-2/neu Testing in Breast Cancer
2003 · Pathology Patterns Reviews · 62 citations
https://doi.org/10.1309/949fpq1aq3p0rlc0
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
2022 · JTO Clinical and Research Reports · 41 citations
https://doi.org/10.1016/j.jtocrr.2022.100431
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat